Products
Tavaborole was approved in the United States in 2014 as a solution for external use (Kerydin). The drug is not currently registered in many countries.
Structure and properties
Tavaborole (C7H6BFO2, Mr = 151.9 g/mol) exists as a white powder that is sparingly soluble in water. It is an organic boron compound belonging to the class of benzoxaboroles (oxaboroles).
Effects
Tavaborole (ATC D01AE24) has antifungal properties. The effects are due to selective inhibition of protein synthesis in fungi by inhibition of leucyl-tRNA synthetase, a correcting enzyme belonging to aminoacyl-tRNA synthetases (AARS). The drug forms a stable adduct with the substrate tRNALeu in the enzyme and blocks it in the active site. This inhibits the synthesis of leucyl-tRNALeu. The boron atom in the molecule is critical for binding.
Indications
For the treatment of nail fungus with or .
Dosage
According to the professional information. The drug is applied locally to the nail once daily for 48 weeks.
Contraindications
Tavaborole is contraindicated in case of hypersensitivity. Full precautions can be found in the drug label.
Interactions
There are no known interactions with other drugs.
Adverse effects
Possible adverse effects include local reactions such as skin redness and inflammation and exfoliated skin.
